Inivata and Gustave Roussy Presented Data at World Lung Conference Demonstrating the Clinical Use of Liquid Biopsy Approaches in Lung Cancer Patients when Tissue is Not Available

December 7, 2016

Inivata and Gustave Roussy Presented Data at World Lung Conference Demonstrating the Clinical Use of Liquid Biopsy Approaches in Lung Cancer patients when Tissue is Not Available

Research Triangle Park, NC and Cambridge, UK, December 8, 2016 — Inivata, a global clinical cancer genomics company employing a revolutionary approach to circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology, presented data with collaborators from Gustave Roussy at the 17th World Conference on Lung Cancer in Vienna.   The data generated in the joint project explores the clinical benefit for non-small cell lung cancer (NSCLC) patients treated with osimertinib who were EGFR T790M-positive based on a novel, blood-based liquid biopsy test, InVision™. The researchers looked at response rates specifically in advanced patients with resistance to at least one prior EGFR targeted therapy who were not able to have a tissue biopsy. They found that of the 48 patients tested, 24 patients (50%) were EGFR T790M-positive. Of the 24 positive patients, 9 patients had an allele fraction lower than 0.5%, at frequencies that may be missed using less sensitive assays. For the patients who were treated with osimertinib and evaluable for treatment response, the objective response rate was 62.5% with the remaining patients having stable disease as their best overall response. The study supports the use of liquid biopsies as a surrogate marker for T790M in tumor tissue, avoiding the need for invasive tumor biopsies for personalizing treatment in lung cancer patients.

On December 7, Inivata presented analytical performance data for InVision comparing results from both their Cambridge, UK laboratory as well as their U.S. CLIA certified laboratory.  The data showed high concordance across both laboratories including strong correlation of InVision ctDNA results compared to a digital PCR-based approach.

“We are impressed with the performance of our InVision platform across a variety of clinical scenarios in terms of robustness, reproducibility, and actionability.  The results are encouraging as we continue to generate further data to support clinical use of our InVision platform,” said Clive Morris, Chief Medical Officer of Inivata.

Details of the posters presented are provided below:

Abstract ID: #6389

Title:  Validation and Performance of a Standardized ctDNA NGS Assay across Two Laboratories,

Abstract ID: #5472

Title: Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients

About Inivata

Inivata, a clinical cancer genomics company, is employing the precision of ctDNA analysis to improve personalized healthcare in oncology. Using a simple blood test, ctDNA analysis is a new tool for oncologists to detect cancer, stratify patients, and assess individual response to treatment. Inivata’s proprietary technology is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge. Inivata’s Invision ctDNA assay provides a highly sensitive analysis of a highly-select gene panel to identify actionable mutations for oncologists to treat their patients optimally. In 2016, Inivata opened a CLIA lab in Research Triangle Park, NC and launched a large-scale, prospective clinical validation study of the Company’s ctDNA analysis in lung cancer. For more information and a full listing of investors, please go to www.inivata.com. Follow us on Twitter @Inivata.

Media Contacts:

 Liz Macfadyen

Liz.macfadyen@inivata.com

+44 (0)7739462323

 

Consilium Strategic Communications

Chris Gardner/Laura Thornton

Email: inivata@consilium-comms.com

Phone: +44 (0)20 3709 5700

 

 

 

 

 

 

Discover more news